Latest Viking Therapeutics News & Updates

See the latest news and media coverage for Viking Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Viking Therapeutics

Clinical-stage biotechnology company developing therapies for obesity and metabolic diseases

vikingtherapeutics.com

Headquarters: San Diego, United States
Founded year: 2012
Company type: Public company
Number of employees: 70–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Viking Therapeutics

In short: Viking Therapeutics advanced its obesity drug pipeline, reported a $158.3 million Q1 2026 net loss, and underwent leadership changes.

Company announcements

July 23 Viking Therapeutics

Viking Therapeutics appoints Dorothy Gemmell to Board of Directors

She held executive roles at GoodRx, Capsule, and Havas Life, with experience in commercialization.

July 22 Viking Therapeutics

Viking Therapeutics reports Q2 2026 financial results and update

Phase 3 VANQUISH trials for VK2735 in obesity are fully enrolled, and the company maintains a strong cash position of $502 million.

June 24 Viking Therapeutics

Viking Therapeutics initiates Phase 1 study of VK3019 in healthy adults

The trial evaluates safety, tolerability, and pharmacokinetics of the novel amylin receptor agonist for weight loss.

April 29 Viking Therapeutics

Viking Therapeutics reports Q1 2026 financial results

VANQUISH-1 and -2 trials fully enrolled. Oral VK2735 Phase 3 starts 4Q26. Cash at $603M. Net loss $158.3M.

Media coverage

September 14 Yahoo Finance

Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss

Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3...

September 3 NAI500

Viking Therapeutics Aims High at $92 Target, But Clinical Risks Remain

The global GLP‑1 weight‑loss drug market is on track to approach $100 billion by the end of the decade, currently dominated ...

September 1 Yahoo Finance

VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3

Investors are now awaiting results from an early-stage study of VK2735 testing different ways to keep weight off after an initial course of treatment.

August 3 MSN

Viking Therapeutics, BioNxt Solutions, and Bausch Health: Clinical success sparks fresh optimism

Moderate Quarterly Results Viking Therapeutics is known for its weight-loss medications; its weight-loss injection, in particular, has recently drawn attention. The company has now released...

Never miss news about Viking Therapeutics

Track Viking Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Viking Therapeutics competitors & trending companies

Browse news for competitors to Viking Therapeutics and other trending companies.